These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9170879)

  • 1. [The influence of anti-interferon-alpha 2a antibodies in initial daily four-week interferon-alpha 2a therapy for chronic hepatitis C].
    Habu D; Mizuno M; Ohnishi K; Watanabe A; Son J; Iwano M; Murakoshi R; Takino T; Mizuma Y; Kobayashi M
    Nihon Shokakibyo Gakkai Zasshi; 1997 May; 94(5):319-27. PubMed ID: 9170879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection.
    Milella M; Antonelli G; Santantonio T; Currenti M; Monno L; Mariano N; Angarano G; Dianzani F; Pastore G
    Liver; 1993 Jun; 13(3):146-50. PubMed ID: 8336526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
    Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
    J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.
    Douglas DD; Rakela J; Lin HJ; Hollinger FB; Taswell HF; Czaja AJ; Gross JB; Anderson ML; Parent K; Fleming CR
    Dig Dis Sci; 1993 Apr; 38(4):601-7. PubMed ID: 8384978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in antibody titers to hepatitis C virus following interferon therapy for chronic infection.
    Urushihara A; Sodeyama T; Matsumoto A; Tanaka E
    J Med Virol; 1994 Apr; 42(4):348-56. PubMed ID: 7519250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C.
    Giannelli G; Antonelli G; Fera G; Del Vecchio S; Riva E; Broccia C; Schiraldi O; Dianzani F
    Clin Exp Immunol; 1994 Jul; 97(1):4-9. PubMed ID: 8033418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha.
    Carreño V; Tapia L; Ryff JC; Quiroga JA; Castillo I
    J Med Virol; 1992 Jul; 37(3):215-9. PubMed ID: 1331310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a.
    Negro F; Baldi M; Mondardini A; Leandro G; Chaneac M; Manzini P; Abate ML; Zahm F; Dastoli G; Ballaré M
    Gastroenterology; 1994 Aug; 107(2):479-85. PubMed ID: 8039625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
    Bjøro K; Bell H; Myrvang B; Skaug K; Raknerud N; Sandvei P; Størseth S; Ritland S; Lund-Tønnesen S; Bucher A; Hellum KB
    Scand J Gastroenterol; 2002 Mar; 37(3):344-9. PubMed ID: 11916198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
    Aiyama T; Yoshioka K; Hirofuji H; Kusakabe A; Yamada M; Tanaka K; Kakumu S
    Dig Dis Sci; 1994 Oct; 39(10):2244-9. PubMed ID: 7924750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmunity during alpha-interferon therapy for chronic hepatitis C.
    Yoshikawa M; Sakamoto T; Mitoro A; Mochi T; Tsujii H; Koizumi M; Yoshiji H; Sakaguchi Y; Fukui H; Nakano H
    Gastroenterol Jpn; 1993 May; 28 Suppl 5():109-14. PubMed ID: 8359620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN.
    Milella M; Antonelli G; Santantonio T; Giannelli G; Currenti M; Monno L; Turriziani O; Pastore G; Dianzani F
    Hepatogastroenterology; 1995 Jul; 42(3):201-4. PubMed ID: 7590565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis.
    Magrin S; Craxì A; Fabiano C; Fiorentino G; Marino L; Almasio P; Pinzello GB; Palazzo U; Vitale M; Maggio A
    J Med Virol; 1992 Nov; 38(3):200-6. PubMed ID: 1283753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quantitative humoral immune response to the hepatitis C virus is correlated with disease activity and response to interferon-alpha.
    Löhr HF; Elste C; Dienes HP; Michel G; Braun HB; Meyer zum Büschenfelde KH; Gerken G
    J Hepatol; 1996 Sep; 25(3):292-300. PubMed ID: 8895007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of interferons in treating children with chronic hepatitis C.
    Matsuoka S; Mori K; Nakano O; Yuasa Y; Taguchi Y; Hayabuchi Y; Kuroda Y
    Eur J Pediatr; 1997 Sep; 156(9):704-8. PubMed ID: 9296534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term follow-up of chronic hepatitis C after treatment with recombinant interferon alpha-2a].
    Hopf U; Küther S; König V; Heuft H; Berg T; Bauditz J; Soltani K; Lobeck H; Huhn D
    Z Gastroenterol; 1994 Aug; 32(8):425-30. PubMed ID: 7975783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus RNA and anti-N14 antibody levels during interferon alpha therapy for chronic hepatitis C.
    Oketani M; Tanaka K; Sho Y; Maeda E; Miyazaki H; Arima T
    Intern Med; 1994 Oct; 33(10):588-92. PubMed ID: 7530068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the presence of serum autoantibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C?
    Wada M; Kang KB; Kinugasa A; Shintani S; Sawada K; Nishigami T; Shimoyama T
    Intern Med; 1997 Apr; 36(4):248-54. PubMed ID: 9187562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.
    Hino K; Sainokami S; Shimoda K; Iino S; Wang Y; Okamoto H; Miyakawa Y; Mayumi M
    J Med Virol; 1994 Mar; 42(3):299-305. PubMed ID: 7516422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.